GlassScriptPhysician profile
Danielle L Geiger
NPI 1598735763
$4,751.66
in general payments reported to CMS, 2019-2025
20 companies · $2,572 in 2025
The $2,572 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $303 · 2022: $803 · 2023: $738 · 2024: $336 · 2025: $2,572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,774 · Food and Beverage: $1,072 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,774.00 |
| Food and Beverage | $1,072.01 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $979.00 | 2022-2025 | Zynyz |
| Avyxa Pharma, LLC | $800.00 | 2025 | |
| Asd Specialty Healthcare, LLC | $754.32 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $644.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $480.10 | 2023-2024 | Imfinzi |
| Emd Serono, INC. | $206.77 | 2021-2025 | |
| Genzyme Corporation | $172.24 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $112.74 | 2021 | |
| Genentech, INC. | $106.60 | 2023-2025 | Itovebi |
| Seagen INC. | $99.99 | 2022 | |
| Amgen INC. | $73.76 | 2022-2025 | Vectibix, Blincyto |
| Kite Pharma, INC. | $64.97 | 2023-2024 | Yescarta |
| Pfizer INC. | $61.06 | 2023-2025 | |
| Abbvie INC. | $48.09 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $33.30 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $32.94 | 2025 | Trodelvy |
| Siemens Medical Solutions USA, INC. | $23.83 | 2024 | |
| Novartis Pharmaceuticals Corporation | $21.57 | 2022 | |
| Verity Pharmaceuticals INC. | $20.44 | 2023 | Trelstar |
| Cti Biopharma Corp. | $15.94 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Geiger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.